About Crown Bioscience
Crown Bioscience is a global Contract Research Organization providing preclinical and translational platforms to advance drug discovery and development.
Crown Bioscience is driven by the need to advance scientific knowledge by embracing innovation and partnering with biopharmaceutical companies to solve some of today's challenges in oncology, immuno-oncology and immune-mediated inflammatory diseases. They are a global company with over 900 employees across nine facilities in the United States, Europe, and APAC.
Crown Bioscience delivers a comprehensive suite of biological services and models, including: In vitro, in vivo, and ex vivo. They are the only preclinical CRO to provide tumor organoid services utilizing HUB technology. In addition to offering CDX and syngeneic models, cell-based screening platforms, they are proud to boast the world’s largest commercially available PDX collection.
The company provides high content imaging solutions and analysis of 3D in vitro models, such as organoids and spheroid cultures, and a 3D Ex Vivo Patient Tissue Platform, to leverage the infinite possibilities of scientific innovation.
Further, their biomarker services include a range of end point testing assays and post in vivo and in vitro study readouts developed to optimize therapeutic benefit and discover biomarkers. Included in their biomarker services is range of assays such as ELISA, IHC, FACS, clinical chemistry, PCR and NGS-based genomics, bioinformatics and big data analysis.
In partnership with their customers, Crown Bioscience aims to realize a world where every patient gets the right treatment, at the right time.